biostudies-literatureUnknown21(1)Langedijk ACPfizer Inc. Ahuva Averin, Erin Quinn, and Mark Atwood are employees of Avalere HealthThe European Medicines Agency has authorized two interventions to prevent lower respiratory tract disease due to respiratory syncytial virus (RSV-LRTD) in infants: nirsevimab, a monoclonal antibody, and bivalent stabilized prefusion F subunit maternal vaccine (RSVpreF). In the Netherlands, RSV-LRTD protection is recommended for all infants with nirsevimab given preferential recommendation over RSVpreF. We evaluated cost-effectiveness of various intervention strategies to prevent RSV in the Netherlands. We employed a cohort model to evaluate clinical and economic outcomes associated with RSV-LRTD during the first year of life among infants receiving RSVpreF with complementary nirsevimab and, alternatively, nirsevimab alone versus no intervention. Model inputs, based principally on Dutch datHuman vaccines & immunotherapeutics2521912https://www.ebi.ac.uk/biostudies/studies/S-EPMC12934181biostudies-literatureCost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands.PMC12934181Langedijk ACQuinn ESmit Lvan den Boer JAverin AMendes DHarteveld Lvan den Dungen FAtwood Mvan Houten MLaw AfalseCost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands.The European Medicines Agency has authorized two interventions to prevent lower respiratory tract disease due to respiratory syncytial virus (RSV-LRTD) in infants: nirsevimab, a monoclonal antibody, and bivalent stabilized prefusion F subunit maternal vaccine (RSVpreF). In the Netherlands, RSV-LRTD protection is recommended for all infants with nirsevimab given preferential recommendation over RSVpreF. We evaluated cost-effectiveness of various intervention strategies to prevent RSV in the Netherlands. We employed a cohort model to evaluate clinical and economic outcomes associated with RSV-LRTD during the first year of life among infants receiving RSVpreF with complementary nirsevimab and, alternatively, nirsevimab alone versus no intervention. Model inputs, based principally on Dutch dat2025-01-01T00:00:00Z2025 Dec2026-07-16T21:37:53.354Z2026-07-10T03:16:02.873ZS-EPMC129341814056104710.1080/21645515.2025.2521912